Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Grant R Goodman"'
Autor:
Giulio, Barteselli, Grant R, Goodman, Yogesh, Patel, Ivor, Caro, Cloris, Xue, Samuel, McCallum
Publikováno v:
Drug Safety. 45:1491-1499
Serous retinopathy can be associated with MEK inhibitors, including cobimetinib. We present results of an integrated safety analysis to further characterize ocular functional and structural changes due to serous retinopathy.Four studies evaluating co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b18954a5696b9b0c5d18bb28085315f
https://doi.org/10.1007/s40264-022-01248-2
https://doi.org/10.1007/s40264-022-01248-2
Autor:
Antonia R. Sepulveda, Paul B. Chapman, Lynn M. Schuchter, David C. Metz, Anil K. Rustgi, Grant A. McArthur, Grant R. Goodman, Jeffrey A. Sosman, Keith T. Flaherty, Kenneth Y. Tsai, Jennifer J.D. Morrissette, Xiaowei Xu, Igor Puzanov, Georgina V. Long, Matteo S. Carlino, Katherine L. Nathanson, Armando Del Portillo, Shengfu Piao, Xiaohong Ma, Kathryn E. Hamilton, Ravi K. Amaravadi
Purpose: BRAF inhibitors (BRAFi) extend survival in BRAF-mutant melanoma but can promote the growth of Ras-mutant neoplasms. This study determined if gastrointestinal polyps found in BRAFi-treated patients harbored Ras mutations.Experimental Design:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::412963722f13ee08e08968db5b292b14
https://doi.org/10.1158/1078-0432.c.6524708
https://doi.org/10.1158/1078-0432.c.6524708
Supplemental Figure 1 from Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors
Autor:
Antonia R. Sepulveda, Paul B. Chapman, Lynn M. Schuchter, David C. Metz, Anil K. Rustgi, Grant A. McArthur, Grant R. Goodman, Jeffrey A. Sosman, Keith T. Flaherty, Kenneth Y. Tsai, Jennifer J.D. Morrissette, Xiaowei Xu, Igor Puzanov, Georgina V. Long, Matteo S. Carlino, Katherine L. Nathanson, Armando Del Portillo, Shengfu Piao, Xiaohong Ma, Kathryn E. Hamilton, Ravi K. Amaravadi
Supplemental Figure 1. Endoscopic and histological H&E images of colonic polyps in a Magnification: 10X (bottom left); 200X (bottom right) BRAF mutant melanoma patient treated with long-term vemurafenib.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e3be20d32c4e73e3de0357ac541e3b1
https://doi.org/10.1158/1078-0432.22461176
https://doi.org/10.1158/1078-0432.22461176
Autor:
Antonia R. Sepulveda, Paul B. Chapman, Lynn M. Schuchter, David C. Metz, Anil K. Rustgi, Grant A. McArthur, Grant R. Goodman, Jeffrey A. Sosman, Keith T. Flaherty, Kenneth Y. Tsai, Jennifer J.D. Morrissette, Xiaowei Xu, Igor Puzanov, Georgina V. Long, Matteo S. Carlino, Katherine L. Nathanson, Armando Del Portillo, Shengfu Piao, Xiaohong Ma, Kathryn E. Hamilton, Ravi K. Amaravadi
Supplemental Methods from Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18069e65730624323c09c77a3cb300e1
https://doi.org/10.1158/1078-0432.22461173.v1
https://doi.org/10.1158/1078-0432.22461173.v1
Autor:
Suzanne Trudel, Nizar J. Bahlis, Andrew Spencer, Rayan Kaedbey, Paula Rodriguez Otero, Simon J Harrison, Chihunt Wong, Grant R. Goodman, Rin Nakamura, Voleak Choeurng, James Cooper, Maria-Victoria Mateos
Publikováno v:
Blood. 140:1363-1365
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::663c8f7c47b17959cc6f5e6565b1540d
https://doi.org/10.1182/blood-2022-159381
https://doi.org/10.1182/blood-2022-159381
Autor:
Enric Bertran, Grant R. Goodman, Harper Forbes, Weijiang Zhang, M. Mathisen, Lev V. Demidov, Sang Joon Shin, Yuyao Song
Publikováno v:
Clinical Pharmacology in Drug Development. 10:39-45
The effects of itraconazole, a strong CYP3A4 inhibitor, on the steady-state pharmacokinetics of vemurafenib were evaluated in a phase 1, multicenter, open-label, fixed-sequence study. Patients with BRAFV600 mutation-positive metastatic malignancies r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b7b6fd6781c799711ce62e5e2475872
https://doi.org/10.1002/cpdd.822
https://doi.org/10.1002/cpdd.822
Autor:
Andrzej Mackiewicz, Karl D. Lewis, G. Hooper, P.A. Ascierto, Matthew Wongchenko, C. Herbert, I. Bondarenko, Piotr Rutkowski, Lev V. Demidov, Grant R. Goodman, B. Simmons, Mario Mandalà, A.M. Di Giacomo, Dirk Schadendorf, C. Ye, Alexander Guminski, Yibing Yan
Publikováno v:
Annals of Oncology. 31:153-159
Background We conducted a retrospective exploratory analysis to evaluate the effects of baseline tumour immune infiltrate on disease-free survival (DFS) outcomes in patients with fully resected stage IIC–IIIC melanoma receiving adjuvant vemurafenib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ce6791f09f8e9bfab729500197285e1
https://doi.org/10.1016/j.annonc.2019.10.002
https://doi.org/10.1016/j.annonc.2019.10.002
Autor:
Anna Maria Di Giacomo, Grant R. Goodman, Christopher Herbert, Lev V. Demidov, Barbara Merelli, Piotr Rutkowski, B. Simmons, Andrzej Mackiewicz, C. Ye, Dirk Schadendorf, Brim Investigators, Agnes Hong, Alexander Guminski, Igor Bondarenko, Paolo A. Ascierto, Karl D. Lewis
Publikováno v:
European Journal of Cancer. 123:155-161
Aim of study The aim of the study was to assess the impact of treatment with adjuvant vemurafenib monotherapy on health-related quality of life (HRQOL) in patients with resected stage IIC–IIIC melanoma. Methods The phase 3 BRIM8 study (NCT01667419)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79963362aa6b5f2513e99f3d59dd6688
https://doi.org/10.1016/j.ejca.2019.09.019
https://doi.org/10.1016/j.ejca.2019.09.019
Autor:
Ezra E.W. Cohen, Grant R. Goodman, Melissa Lynne Johnson, T. Pham, Lisa Licitra, J. Fayette, K. Cvijovic, K.J. Harrington, C. Matheny, M. Afshari, Kimberly Komatsubara, Lan Wang, Yibing Yan, H. Tang, Amanda Psyrri, S-H Lee, Deborah Jean Lee Wong, H.-F. Kao, Maura L. Gillison, Nuttapong Ngamphaiboon
Publikováno v:
Annals of Oncology. 32:S814-S815
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ec64611a7e9253527c254cf04f9dae6
https://doi.org/10.1016/j.annonc.2021.08.1337
https://doi.org/10.1016/j.annonc.2021.08.1337
Autor:
Weijiang, Zhang, Michael, Mathisen, Grant R, Goodman, Harper, Forbes, Yuyao, Song, Enric, Bertran, Lev, Demidov, Sang Joon, Shin
Publikováno v:
Clinical pharmacology in drug developmentReferences. 10(1)
The effects of itraconazole, a strong CYP3A4 inhibitor, on the steady-state pharmacokinetics of vemurafenib were evaluated in a phase 1, multicenter, open-label, fixed-sequence study. Patients with BRAF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f37b4b7fd4a2067e153582c5f444654d
https://pubmed.ncbi.nlm.nih.gov/32602215
https://pubmed.ncbi.nlm.nih.gov/32602215